List of Excipients in Branded Drug EDEX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Endo USA Inc	EDEX	alprostadil	52244-010	ALFADEX
Endo USA Inc	EDEX	alprostadil	52244-010	LACTOSE
Endo USA Inc	EDEX	alprostadil	52244-010	SODIUM CHLORIDE
Endo USA Inc	EDEX	alprostadil	52244-010	WATER

EDEX Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 4, 2026

EDEX is an intracavernosal alprostadil product supplied as a sterile, single-use cartridge that combines a low-dose prostaglandin active ingredient with a cyclodextrin-based formulation and a proprietary delivery device. Its commercial opportunity is no longer driven by basic composition-of-matter exclusivity. It depends on device usability, cartridge compatibility, formulation stability, manufacturing reliability, and differentiation from compounded alprostadil and competing erectile-dysfunction therapies.

The principal commercial opening is a generic or 505(b)(2) product that matches EDEX’s clinical performance while reducing device cost, improving shelf life, or offering a more convenient administration system. EDEX is a small-molecule drug, not a biologic, so biosimilar regulation does not apply. Generic applicants would pursue an ANDA or, for a materially different formulation or device, a 505(b)(2) pathway.

What is EDEX and how is it formulated?

EDEX is alprostadil for intracavernosal injection. The product is approved in 10 mcg, 20 mcg, and 40 mcg strengths for the treatment of erectile dysfunction of neurogenic, vasculogenic, psychogenic, or mixed etiology.[1]

The active ingredient is alprostadil, also known as prostaglandin E1. EDEX uses alprostadil alfadex, a complex of alprostadil with alpha-cyclodextrin. The formulation is reconstituted before injection using the supplied dual-chamber cartridge and delivery system.

Attribute	EDEX
Active ingredient	Alprostadil
Dosage form	Intracavernosal injection
Strengths	10 mcg, 20 mcg, 40 mcg
Formulation approach	Alprostadil alfadex complex with excipients
Delivery system	Single-use dual-chamber cartridge and injector
Route	Intracavernosal
FDA application	NDA 020379
Product category	Small-molecule drug-device combination
Biosimilar status	Not applicable
Main competitors	CAVERJECT, compounded alprostadil injections, oral PDE5 inhibitors, intraurethral alprostadil

The EDEX label identifies alpha-cyclodextrin-related formulation technology, lactose, citrate, and pH-adjusting agents as part of the product presentation.[1] The exact quantitative composition and manufacturing controls are important because the product contains a very small quantity of a chemically unstable active ingredient.

Which excipients are used in EDEX?

The key excipient strategy combines solubilization, stabilization, buffering, and dry-state protection.

Alpha-cyclodextrin

Alpha-cyclodextrin is the most commercially important excipient in EDEX. It forms an inclusion complex with alprostadil, improving handling and enabling presentation of the active ingredient in a dry or otherwise stabilized form before reconstitution.

Cyclodextrin selection affects:

• Alprostadil complexation
• Reconstitution time
• Chemical stability
• Free-drug concentration
• Local tolerability
• Compatibility with the cartridge materials
• Manufacturing yield

A substitute cyclodextrin would not be a simple excipient swap. A formulation using beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin, sulfobutylether-beta-cyclodextrin, or another complexing agent could trigger comparative pharmaceutical development and potentially a 505(b)(2) application rather than a straightforward ANDA, depending on the product’s formulation and clinical differences.

Lactose

Lactose acts primarily as a bulking and matrix-forming excipient. In a low-dose injectable product, the excipient mass is much larger than the alprostadil dose. Lactose therefore affects powder structure, fill uniformity, reconstitution, and dose presentation.

The critical technical issues are:

• Uniform distribution of microgram quantities of alprostadil
• Control of powder density and fill weight
• Moisture protection
• Prevention of degradation during storage
• Consistent release into the diluent

Citrate buffer

Citrate provides pH control during storage and after reconstitution. Alprostadil is sensitive to chemical degradation, and pH can affect both stability and local injection tolerability.

A competing product could use phosphate, acetate, histidine, or another buffer system, but the substitution would require evaluation of:

• pH over shelf life
• Degradation products
• Container compatibility
• Osmolality
• Injection-site tolerability
• Interaction with the cyclodextrin complex

Hydrochloric acid and sodium hydroxide

These agents adjust formulation pH. They are not likely to create meaningful stand-alone commercial differentiation, but they can affect product quality when combined with the active complex, buffer, cartridge, and diluent.

Water and cartridge materials

The reconstitution medium and the cartridge are part of the product’s functional formulation. Water quality, extractables and leachables, stopper performance, seal integrity, and adsorption to contact surfaces can affect product quality even when the nominal excipient composition is unchanged.

What excipient strategy is most attractive for an EDEX competitor?

The strongest strategy is to preserve the clinical behavior of alprostadil while improving one or more manufacturing or usability attributes.

Strategy	Technical objective	Regulatory implication	Commercial value
Retain alprostadil alfadex	Closest formulation match	Potential ANDA pathway if equivalence is demonstrated	Lowest clinical and regulatory risk
Use a different cyclodextrin	Improve stability or complexation	May require 505(b)(2) justification	Potential differentiation, higher development cost
Develop a ready-to-use solution	Eliminate reconstitution	Likely formulation and stability burden	Better convenience, possible premium positioning
Develop a lower-volume injection	Reduce injection discomfort	Requires dose-delivery and local tolerability data	Patient and prescriber differentiation
Use a prefilled syringe	Simplify administration	Device and combination-product review	Lower handling burden
Improve moisture barrier	Extend shelf life	Stability data required	Lower waste and improved distribution
Develop a preservative-free multidose system	Reduce preservative exposure	Complex sterility and in-use stability program	Potential specialty-market opportunity
Create a compounded-pharmacy platform	Offer customized dosing	State and federal compounding controls	Faster niche entry, lower IP protection

A formulation that retains alprostadil alfadex and the same dose strengths is the most defensible path for a conventional generic. A reformulated ready-to-use product may create a more valuable product but would carry greater development and regulatory risk.

What patents protect EDEX?

EDEX’s current commercial position is unlikely to depend on unexpired composition-of-matter protection for alprostadil. Alprostadil is an old prostaglandin active ingredient, and the product has been marketed for decades.

The relevant protection categories are:

1. Alprostadil and cyclodextrin complexes.
2. Stabilized injectable formulations.
3. Dry powder or dual-chamber cartridge presentations.
4. Injector and cartridge assemblies.
5. Reconstitution methods.
6. Methods of treating erectile dysfunction with intracavernosal alprostadil.
7. Manufacturing processes for low-dose sterile fills.

FDA’s Orange Book is the controlling public source for patents and regulatory exclusivity associated with an approved drug application.[2] Publicly available regulatory information does not indicate that EDEX has a current market exclusivity period comparable to a new chemical entity, pediatric exclusivity period, or active regulatory exclusivity barrier. Any live patent analysis must distinguish patents listed against NDA 020379 from expired historical patents and from patents covering third-party devices or manufacturing processes.

Are EDEX patents still enforceable?

The principal risk is not expected to arise from the alprostadil active ingredient itself. It could arise from:

• A still-enforceable formulation patent
• A cartridge or injector patent
• A manufacturing patent
• A patent owned by a device supplier
• A patent covering a substitute cyclodextrin or ready-to-use presentation

Patent term depends on filing date, patent term adjustment, terminal disclaimers, maintenance fees, and applicable transitional rules. A freedom-to-operate review should therefore cover U.S. patents and applications assigned to the EDEX sponsor, historical manufacturers, injector suppliers, and formulation technology owners.

When does EDEX lose exclusivity?

EDEX’s practical market exclusivity has largely expired. The product is not protected by the type of active-ingredient exclusivity that prevents generic development of a recently approved innovative drug.

Exclusivity category	EDEX position
New chemical entity exclusivity	Expired or not applicable to current competition
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current barrier identified
Biologic exclusivity	Not applicable
Regulatory exclusivity	No current significant period identified
Orange Book patent barrier	Must be confirmed against the current FDA listing
Device-related protection	Potentially relevant, depending on claim scope and expiration
Formulation protection	Historical and potentially jurisdiction-specific

The key distinction is between loss of regulatory exclusivity and loss of commercial differentiation. EDEX can remain commercially differentiated by its delivery system even after the underlying drug has become legally accessible to generic developers.

Are there Paragraph IV challenges to EDEX?

A Paragraph IV certification would be relevant if an ANDA applicant challenged an unexpired Orange Book-listed patent for EDEX. Public information does not establish a current, material Paragraph IV litigation campaign against EDEX comparable to the litigation surrounding high-revenue branded drugs.

An ANDA applicant could instead:

• Certify that no relevant patent is listed.
• Submit a Paragraph III certification and delay launch until patent expiry.
• Submit a Paragraph IV certification against a listed patent.
• Pursue a 505(b)(2) application if it changes the formulation, delivery system, or route-specific product characteristics.

For EDEX, the most likely legal pathway is a formulation-and-device assessment followed by an ANDA if the applicant can demonstrate pharmaceutical equivalence, bioequivalence or equivalent performance, and acceptable device functionality.

What FDA regulatory pathway applies to an EDEX generic?

The FDA pathway depends on how closely the proposed product matches EDEX.

ANDA pathway

An ANDA is most plausible when the proposed product has:

• The same active ingredient
• The same strength options
• The same route of administration
• The same dosage form
• Equivalent excipient functions
• Equivalent or sufficiently comparable delivery performance
• A device that meets applicable combination-product requirements

The principal development risks are not traditional systemic bioequivalence. Intracavernosal delivery creates local exposure, and alprostadil is administered at microgram doses. Applicants may need comparative in vitro performance, pharmacokinetic support where feasible, local tolerability data, and device-performance testing.

505(b)(2) pathway

A 505(b)(2) application is more suitable for:

• A different cyclodextrin
• A ready-to-use solution
• A different cartridge geometry
• A new dose-volume relationship
• A new injector
• A new concentration
• Modified stability or reconstitution behavior

This pathway permits reliance on FDA findings for a listed drug while supporting the differences with new data. It can create stronger product differentiation but usually requires a more extensive clinical and formulation package than an ANDA.

What formulation patents could protect an EDEX competitor?

The most valuable patent claims would cover technical features that are difficult to design around and visible to customers.

High-value claim categories

• Alprostadil-cyclodextrin complexes with defined molar ratios
• Moisture-controlled dry compositions
• Reconstitution systems with specified dissolution times
• Low-dose powder blends with content-uniformity controls
• Cartridge systems that separate drug powder and diluent
• Injector mechanisms that control dose delivery
• Stabilized ready-to-use alprostadil solutions
• Preservative-free multidose systems
• Formulations with reduced injection-site pain
• Specific container-closure systems that limit adsorption or degradation

A patent limited to the use of lactose or citrate would generally provide weak commercial protection because competitors may substitute functionally equivalent excipients. A patent tied to a defined complex, stability profile, cartridge configuration, or measurable delivery performance is more valuable.

How strong is the EDEX patent estate?

The patent estate is likely moderate to weak for the basic drug but potentially stronger for integrated formulation-device combinations.

Patent layer	Relative strength	Design-around risk
Alprostadil composition of matter	Low	Very high
General erectile-dysfunction method of use	Low	High
Alprostadil-cyclodextrin complex	Moderate, depending on claim scope	Moderate
Specific excipient ratio	Low to moderate	High
Dual-chamber cartridge	Moderate	Moderate
Injector mechanism	Moderate to strong if device-specific	Moderate
Ready-to-use stabilized solution	Potentially strong	Moderate
Manufacturing process	Variable	Moderate to high
Trade secrets and process know-how	Commercially relevant	Difficult to assess publicly

Trade secrets may be more important than patents in maintaining EDEX’s product quality. Low-dose sterile filling, powder blending, moisture control, cartridge loading, and stability management can create barriers that are difficult to reproduce without process development.

What manufacturing barriers affect EDEX competition?

EDEX has several technical barriers that do not appear in a conventional tablet generic.

Low-dose content uniformity

The alprostadil dose is measured in micrograms. The manufacturer must distribute a small amount of active ingredient uniformly through a larger excipient matrix. Blend segregation, electrostatic charging, particle-size variation, and loss to manufacturing surfaces can affect dose accuracy.

Stability and oxidation control

Alprostadil is susceptible to degradation. The manufacturing process must control oxygen, moisture, light, temperature, and contact with reactive surfaces. Stability programs must evaluate potency, impurities, reconstitution performance, and container closure.

Sterile manufacturing

The product requires sterile or aseptic production and a reliable container-closure system. Microbial contamination, endotoxin, particulate matter, and seal integrity are material risks.

Device integration

The cartridge and injector must deliver the intended dose consistently. A generic product cannot be assessed only as a vial or powder. The device must be validated for assembly, dose accuracy, usability, and compatibility with the formulation.

What commercial opportunities exist for EDEX?

The opportunity is concentrated in differentiated delivery and cost reduction rather than broad erectile-dysfunction market expansion.

Generic EDEX

A lower-cost equivalent could compete with branded EDEX and reduce payer and patient costs. The product would benefit from the established clinical use of intracavernosal alprostadil and the absence of a need to prove a new therapeutic mechanism.

Premium ready-to-use product

A ready-to-use injection could eliminate reconstitution steps and reduce administration errors. The product could command a premium if it demonstrates adequate shelf life and lower handling burden.

Prefilled or autoinjector presentation

A prefilled syringe or dose-controlled injector could address training and usability barriers. Device simplicity is commercially important because intracavernosal injection has a higher administration burden than oral PDE5 inhibitors.

Specialty pharmacy and telehealth distribution

EDEX competitors can use specialty pharmacies, urology clinics, and telehealth channels. Controlled distribution can support titration services, patient education, and recurring prescription revenue.

Compounded formulation replacement

Compounded alprostadil products are often less standardized in presentation and may have different stability and quality profiles. An FDA-approved, convenient product could compete by emphasizing validated potency, sterility, labeling, and consistent delivery.

Combination intracavernosal products

Compounded bimix and trimix products combine alprostadil with other vasodilators. A commercial product using more than one active ingredient could target patients who do not respond adequately to alprostadil alone, but it would face a more complex regulatory and clinical program.

How does EDEX compare with CAVERJECT?

EDEX and CAVERJECT both use intracavernosal alprostadil, but their formulation and delivery systems differ.

Attribute	EDEX	CAVERJECT
Active ingredient	Alprostadil	Alprostadil
Route	Intracavernosal	Intracavernosal
Dose range	10, 20, 40 mcg	Product-specific strengths and presentations
Formulation approach	Alprostadil alfadex-based presentation	Alprostadil formulation with its own excipient and reconstitution system
Device	Dual-chamber cartridge and injector	Vial or device presentation, depending on product
Main differentiation	Cartridge convenience and integrated delivery	Established product line and clinical familiarity
Generic opportunity	Formulation-device equivalent or 505(b)(2)	Separate formulation and device analysis required

A competitor cannot assume that an approved generic of one product will be interchangeable with the other. Formulation composition, reconstitution, device operation, and labeling must be assessed separately.

What is the revenue exposure for EDEX?

Public company filings generally do not isolate EDEX revenue from broader specialty or men’s-health portfolios. A precise product-level revenue estimate is therefore not established by public regulatory data.

The commercial exposure can be assessed through market characteristics:

• Intracavernosal therapy is a niche segment relative to oral erectile-dysfunction drugs.
• Revenue is recurring because patients use the product repeatedly.
• Device and training barriers limit rapid conversion.
• Compounded products create price competition.
• Generic entry would likely pressure net price before eliminating demand.
• Premium delivery systems could preserve margin after active-ingredient competition begins.

The highest-value opportunity is unlikely to be a commodity vial. It is a reliable, easy-to-use, competitively priced delivery system supported by specialty distribution.

What generic launch scenarios exist for EDEX?

Scenario	Product profile	Likely market effect
First ANDA equivalent	Same active, strength, and core formulation	Rapid price pressure
Multiple ANDA entrants	Several equivalent cartridge products	Significant net-price erosion
505(b)(2) ready-to-use product	Different formulation or presentation	Premium niche positioning
Device-only improvement	Same drug with easier administration	Partial brand retention and differentiation
Compounded low-cost product	Customized alprostadil or combination therapy	Persistent price ceiling
Combination product	Alprostadil plus other agents	Expansion into nonresponders, higher regulatory burden

The first approved equivalent may capture substantial pharmacy and payer demand, but device compatibility and prescriber familiarity could delay full substitution. Branded EDEX could retain patients who value the existing injector, while price-sensitive patients and payers shift to lower-cost alternatives.

What is the geographic patent and regulatory outlook?

The U.S. opportunity is shaped by FDA approval, Orange Book status, ANDA litigation, and U.S. device requirements. Europe and other markets require separate analysis because:

• Patent terms differ by jurisdiction.
• Supplementary protection certificates may affect historical products.
• National reimbursement varies.
• Device regulations may be separate from medicinal-product approval.
• Compounding rules differ.
• Alprostadil presentations are not necessarily approved under the same brand or formulation.

A global launch should prioritize jurisdictions where the product has an established reimbursement pathway, where injectable erectile-dysfunction therapy is commercially accepted, and where local manufacturing or device-registration requirements do not offset the price opportunity.

Key Takeaways

• EDEX is an alprostadil intracavernosal injection supplied through a formulation-device combination.
• Alpha-cyclodextrin, lactose, citrate, and pH-adjusting agents support the product’s formulation strategy.
• The basic alprostadil active ingredient does not provide a meaningful modern exclusivity barrier.
• The main IP risks are formulation, cartridge, injector, manufacturing, and third-party device patents.
• EDEX is not subject to biosimilar competition.
• An ANDA is the most direct route for a close formulation and device equivalent.
• A 505(b)(2) application is more suitable for a ready-to-use solution, new cyclodextrin, new concentration, or materially different device.
• The strongest commercial opportunities are generic cost reduction, ready-to-use delivery, prefilled systems, improved stability, and specialty-pharmacy distribution.
• Manufacturing barriers include microgram-dose uniformity, sterile filling, moisture control, alprostadil degradation, and device-dose accuracy.
• Product-level EDEX revenue is not separately disclosed in widely available public filings, so market value should be modeled through prescription volume, reimbursement, net price, and generic-entry timing.

FAQs

Is EDEX a biologic drug?

No. EDEX contains alprostadil, a small-molecule prostaglandin. A competing product would use an ANDA or 505(b)(2) pathway, not a biosimilar application.

Can a generic EDEX use different excipients?

Possibly. A generic applicant must demonstrate that the differences do not affect safety, effectiveness, performance, or bioequivalence. A material formulation change may require a 505(b)(2) application.

Does EDEX require refrigeration?

Storage requirements depend on the approved product presentation and label. The commercial value of improved room-temperature stability would depend on validated stability data and a revised FDA-approved labeling position.

Can a competitor patent a new EDEX injector?

Yes. A new injector may be patentable if it provides a novel and nonobvious dose-control, cartridge, safety, usability, or administration mechanism. Device patents would not automatically protect the underlying alprostadil formulation.

Is compounded trimix a direct substitute for EDEX?

It is a clinical and commercial alternative, but it is not the same approved product. Trimix typically combines alprostadil with other vasodilators and is subject to different manufacturing, quality, labeling, and regulatory conditions.

References

1. U.S. Food and Drug Administration. (n.d.). EDEX (alprostadil for injection) prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.

4. U.S. Food and Drug Administration. (2022). Drug products, including biological products, that contain nanomaterials: Guidance for industry. FDA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.